Serological Biomarkers in Autoimmune GFAP Astrocytopathy.
Cong-Cong Fu,Lu Huang,Lu-Fen Xu,Li-Hong Jiang,Hui-Lu Li,Sha Liao,Jiajia Yue,Chun Lian,Xin-Guang Yang,You-Ming Long
DOI: https://doi.org/10.3389/fimmu.2022.957361
IF: 7.3
2022-01-01
Frontiers in Immunology
Abstract:Autoimmune glial fibrillary acidic protein astrocytopathy (GFAP-A) is a newly defined meningoencephalomyelitis. The pathogenesis of GFAP-A is not well understood. The present study measured the expression levels of 200 serological cytokines in GFAP-A patients, NMOSD patients and healthy controls (HCs). The correlations between serum cytokine levels and clinical information in GFAP-A patients were analyzed. A total of 147 serological proteins were differentially expressed in GFAP-A patients compared to HCs, and 33 of these proteins were not observed in NMOSD patients. Serum levels of EG-VEGF negatively correlated with GFAP antibody titers, MIP-3 alpha positively correlated with clinical severity in GFAP-A patients, and LIGHT positively correlated with WBC counts and protein levels in the CSF of GFAP-A patients. These results suggest that GFAP and AQP4 astrocytopathy share some common pathology related to TNF signaling. Serum MIP 3 alpha may be a biomarker to assess clinical severity and a potential target for therapy of autoimmune GFAP astrocytopathy.
What problem does this paper attempt to address?